Akkad W, Salem B, Freeman JW, Huntington MK. Longitudinally extensive transverse myelitis following vaccination with nasal attenuated novel influenza A(H1N1) vaccine. Arch Neurol 2020;67:agosto. [Ref.ID 103716]

Andersen NN, Pasternak B, Andersson M, Nielsen NM, Jess T. Risk of demyelinating diseases in the central nervous system in patients with inflammatory bowel disease treated with tumor necrosis factor inhibitors. JAMA Intern Med 2015;175:1990-2. [Ref.ID 99751]

Bryan P, Seabroke S, Davies C. H1N1 vaccine safety: real-time surveillance in the UK. Lancet 2010;376:417-8. [Ref.ID 89074]

Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, Law B, Miller E, Andrews N, Stowe J, Salmon D, Vannice K, Izurieta HS, Akhtar A, Gold M, Oselka G, Zuber P, Pfeifer D, Vellozzi C. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009;374:2115-22. [Ref.ID 87323]

Haug C. The risks and benefits of HPV vaccination. JAMA 2009;302:795-6. [Ref.ID 86576]

Geier DA, Geier MR. Chronic adverse reactions associated with hepatitis B vaccination. Ann Pharmacother 2002;36:1970. [Ref.ID 64482]

Verstappen CCP, Heimans JJ, Hoekman K, Postma T J. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003;63:1549-63. [Ref.ID 64215]

Jacobs LD, Beck RW, Simon JH, Kinkel P, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW, and the CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. Ann Intern Med 2000;133:898-904. [Ref.ID 52890]

Duclos P, Ward BJ. Measles vaccines: a review of adverse events. Drug Saf 1998;19:435-54. [Ref.ID 42026]